Birmingham, West Midlands -- (SBWIRE) -- 01/24/2014 -- Value Penny Stocks issues special report on MannKind Corporation (NASDAQ:MNKD), Geron Corporation (NASDAQ:GERN), Logitech International SA (USA) (NASDAQ:LOGI), Nektar Therapeutics (NASDAQ:NKTR).
MannKind Corporation (NASDAQ:MNKD) ended its recent business day with the gain of 1.97% and closed at the price of $5.70 after opening at $5.64. The stock traded during its last trading session with the total volume of 6.92 million shares, as compared to its average volume of 7.41 million shares. MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States.
Will MNKD Continue To Move Higher? Find Out Here
Geron Corporation (NASDAQ:GERN) remained among the day decliners and traded with volume of 6.92 million shares in the last session, as compared to average volume of 5.38 million shares. In comparison with 52 week range of $0.98 - $7.79, it faced lowest price of $5.24 during the last trading session whereas its day highest price was $5.78. The company’s total market capitalization is $736.40 million, along with 128.97 million shares outstanding. Geron Corporation is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
Why Should Investors Buy GERN After The Recent Gain? Just Go Here and Find Out
Logitech International SA (USA) (NASDAQ:LOGI) showed 6.85 million shares in volume during the last trading session, while the average trading volume remained 592,049.00 shares. The stock kicked off its trading session at $15.32 and closed at $16.23 after mounting 22.77%. Logitech International S.A., together with its subsidiaries, engages in the development and marketing of hardware and software products that enable or enhance digital navigation, music and video entertainment, gaming, social networking, and audio and video communication over the Internet, video security, and home-entertainment control worldwide.
For How Long LOGI will Fight for Profitability? Read This Trend Analysis report
Nektar Therapeutics (NASDAQ:NKTR) stock traded during its last trading session with the total traded volume of 6.50 million shares versus its average volume of 715,262.00 shares. The company opened its trade at the price of $13.12 and its closing price was $13.99 after gaining 6.79% for the day. Nektar Therapeutics, a clinical-stage biopharmaceutical company, develops a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms.
Why Should Investors Buy NKTR After The Recent Gain? Just Go Here and Find Out
About Value Penny Stocks:
Value Penny Stocks was made by Two Active traders, Steve and Wilson, whom have made a platform for traders in order to provide traders the #1 Penny Stock Newsletter which actually gives value to your money and makes your portfolio full of profits. We concentrate on small cap stocks that trade on NYSE, NASD, AMEX, OTCBB, and OTC exchanges. These are usually stocks that will trade under $5 a share and offer the utmost potential profit on your short or long term investment. We also devote ourselves to understanding the overall market situations and use this knowledge in order to gain a better perception during our stock picking decisions.
We at ValuePennyStocks.com are engaged in the business of marketing and advertising companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.
Please Read Our Full Disclaimer at: http://www.valuepennystocks.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)